Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

1714 with DOI

2 strong · 8 moderate · 7 weak

Compilations

12026-04-21T02:45:27.372Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:30:10.455Z

notice · info card · emergency

Searches

203 with no results

queries and counts on the build

Claims checked

7655 supported

55 supported · 21 not

Correspondence

0received

consent field ships in Phase 4

Edges

233

derivations recorded for this entity

Complete over 17 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5-mapb/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-02srcDesigner drugs: mechanism of action and adverse effects
  3. 2026-10-02srcNeurochemical binding profiles of novel indole and benzofuran MDMA analogues
  4. 2026-10-02srcThe psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
  5. 2026-10-02srcBenzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques
  6. 2026-10-02srcIntoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate
  7. 2026-10-02srcAlpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature
  8. 2026-10-02srcLocomotor and discriminative stimulus effects of three benzofuran compounds in comparison to abused psychostimulants
  9. 2026-10-02srcSerotonin toxicity involving MDMA (ecstasy) and moclobemide
  10. 2026-10-02srcDeath following consumption of MDAI and 5-EAPB
  11. 2026-10-02srcPostmortem findings of organ damage in novel psychoactive substances users: A comprehensive review
  12. 2026-10-02srcPharmacological profile of novel psychoactive benzofurans
  13. 2026-10-02srcBioisosteric analogs of MDMA: Improving the pharmacological profile?
  14. 2026-10-02srcNovel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine
  15. 2026-10-02srcCross-reactivity of selected benzofurans with commercial amphetamine and ecstasy immunoassays in urine
  16. 2026-10-02srcDeath following ingestion of MDMA (ecstasy) and moclobemide
  17. 2026-10-02srcUK Misuse of Drugs Act 1971 (Amendment) Order 2014 (SI 2014/1106)
  18. 2026-10-02srcACMD Advice on 5- and 6-APB and NBOMe Compounds (TCDO Report)
  19. 2026-09-04issueIssued emergency
  20. 2026-09-04issueIssued info_card
  21. 2026-09-04issueIssued notice
  22. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  23. 2026-06-04publicationPublication — backfill
  24. 2026-04-21revisionRevision 1
  25. 2026-04-21absenceSearched DEA / eCFR (WebFetch - failed) for "5-MAPB DEA schedule I controlled substance benzofuran analog" — no results
  26. 2026-04-21absenceSearched ClinicalTrials.gov for "5-MAPB benzofuran" — no results
  27. 2026-04-21absenceSearched PubMed for "5-APB benzofuran receptor binding affinity monoamine releasing agent serotonin dopamine" — no results
  28. 2026-04-21genGeneration — pipeline-v5 · with 2 morepipeline-v5
  29. 2026-04-21rungeneration run

The same entries, as forms: six forms.